Krsnaa Diagnostics Board Greenlights Sale of Diagnostic Equipment Worth Up to ₹120 Crore

Market snapshot: Krsnaa Diagnostics has announced that its Board of Directors has approved the sale of diagnostic equipment worth up to ₹120 crore. This strategic move is intended to streamline the company's asset management operations. The decision aligns with ongoing efforts to optimize its asset footprint while expanding its diagnostic network across India.

Data Snapshot

• The Board of Directors approved the sale of diagnostic equipment worth up to ₹120 crore to optimize asset management.
• The company reported revenue from operations of ₹235.5 crore in Q1 FY27, representing a 22% YoY increase from ₹193 crore in Q1 FY26.
• EBITDA margin for Q1 FY27 stood at 25%, moderating from 27% in the previous year due to upfront rollout expenses for new diagnostic centers.
• In August 2026, the company proposed a capital expenditure of ₹68.81 crore specifically for purchasing and installing CT scanners, MRI machines, and PET-CT systems.

What's Changed

• The company is shifting from a pure infrastructure-and-hold model to an active asset management strategy.
• The board-approved equipment sale of up to ₹120 crore allows the company to monetize underutilized assets, in contrast with its prior continuous capital deployment phase.
• This move follows a massive 22% YoY increase in revenue to ₹235.5 crore in Q1 FY27, suggesting the company is prioritizing margin stabilization after EBITDA margins moderated to 25% from 27%.

Key Takeaways

• Strategic Capital Allocation: The sale of up to ₹120 crore in diagnostic equipment represents a major step toward enhancing asset turnover and improving capital efficiency.
• Monetizing Underutilized Assets: By liquidating select diagnostic machinery, Krsnaa Diagnostics aims to optimize its balance sheet and improve return on capital employed.
• No Disruption to New Projects: The divestment comes as Krsnaa continues to deploy fresh capital, including ₹68.81 crore earmarked for new radiology and pathology setups.
• Focus on Specialized Segments: Capital freed up from legacy equipment can support the company's recent entry into the high-margin PET-CT diagnostics segment.

SAHI Perspective

Krsnaa Diagnostics' decision to sell up to ₹120 crore of equipment is a positive step toward capital discipline. Historically, the company's radiology-led public-private partnership model has required high upfront capital expenditure, nearly 2.5 times that of pathology-focused peers. While this established a deep competitive moat, it also resulted in stretched asset utilization in newly commissioned laboratories, as reflected in the moderation of Q1 FY27 EBITDA margins to 25%. Recycling capital by disposing of underutilized equipment allows Krsnaa to strengthen its liquidity position without diluting equity or increasing debt, providing a strategic buffer for its new 15-year Punjab PET-CT diagnostic project.

Market Implications

For the market, this decision signals that Krsnaa Diagnostics is prioritizing return ratios and balance sheet liquidity over pure asset accumulation. Reducing the carrying value of fixed assets will lower depreciation drag, which could help expand net profit margins in the medium term. Investors are likely to view this asset optimization favorably, especially given that the company is simultaneously scaling up operations in Rajasthan and Punjab. The improved cash runway should reduce reliance on short-term working capital loans, addressing a historical monitorable for the stock.

Trading Signals

Market Bias: Bullish

The board's approval to sell up to ₹120 crore of equipment provides immediate balance sheet flexibility. This asset-light reallocation, combined with strong Q1 FY27 revenue growth of 22% YoY (₹235.5 crore vs ₹193 crore), points to improving operational leverage and capital efficiency.

Overweight: Healthcare Diagnostics, Asset-Light Healthcare Operators

Underweight: Capital-Intensive Diagnostics

Trigger Factors:

• Execution timelines and final transaction values of the ₹120 crore asset sale.
• Margin recovery in upcoming quarters as upfront costs for the Rajasthan and Punjab PPP projects subside.
• Subsequent utilization rates and volume ramp-ups at the newly signed PET-CT diagnostic facilities.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian diagnostics sector is highly competitive and fragmented, requiring substantial continuous investments in state-of-the-art diagnostic machinery. The radiology-led PPP business model, which is Krsnaa's core differentiator, relies heavily on upfront capital for CT and MRI scanners. Industry trends indicate that diagnostic players are increasingly looking to optimize their asset bases to protect margins against rising operational costs. Managing receivables and optimizing working capital are critical in government partnerships, where payment cycles can occasionally stretch beyond 120 days.

Key Risks to Watch

• Transaction Completion Risk: The sale is capped 'up to' ₹120 crore, and the actual cash realized depends on final contract values with buyers.
• Underutilization of Remaining Assets: If the remaining equipment footprint cannot support contract obligations, service quality in PPP hospitals could suffer.
• Receivables Drag: Delayed payment clearances from state governments could offset cash gains from the sale.

Recent Developments

Krsnaa Diagnostics executed a 15-year concession agreement with the Punjab Health Systems Corporation on September 16, 2026, marking its entry into specialized PET-CT diagnostics. Additionally, the company proposed a ₹68.81 crore capital expenditure in August 2026 for purchasing advanced radiology equipment.

Closing Insight

Krsnaa Diagnostics' tactical shift toward active asset management underscores a maturing corporate strategy. By divesting up to ₹120 crore of equipment while investing in higher-margin specialized domains like Punjab's PET-CT cancer care network, the company is demonstrating a commitment to improving its return profile. Successfully executing this sale will enhance liquidity, providing a strong foundation for sustainable growth in its public-private partnerships.

High Performance Trading with SAHI.